摘要:
4-Chloro-3,5-diaminophenyl acetates having the formula ##STR1## wherein R represents an alkyl group are useful as curing agent for polyurethane elastomer and intermediates for pharmaceutical and agrochemical compounds and are produced by simultaneously nitrating hydrolyzing 4-chlorobenzylcyanide and esterifying the resulting 4-chloro-3,5-dinitrophenyl acetic acid and then reducing the resulting ester.
摘要:
A method for the preparation of polyurethane elastomers in which polyethyleneglycol-bis(4-aminobenzoate) is used as the curing agent to be admixed with the polyurethane formulations. This curing agent imparts considerably extended pot life to the ready-prepared polyurethane composition to be cured by heating into an elastomer having improved properties.
摘要:
A curing agent for polyurethane which has a melting point at most 110.degree. C and comprises a mixture of at least two compounds of the general formula: ##STR1## Wherein n is zero or a positive integer. This curing agent has a low solidifying point and good solubility in solvents and thus is excellent in workability. This curing agent is used for the production of polyurethane highly stabilized in quality.
摘要:
A space diversity system capable of operating accurately over a wide range of received input electric field strengths. With a middle or high received electric field strength, a search operation for the antenna with the highest strength is commenced in response to noise detected in the output of the antenna presently selected. With a low received electric field strength, the search operation is carried out in response to noise such as white noise at all times.
摘要:
A headrest including: a headrest body that supports a head portion of an occupant; a pair of side frame sections that supports the headrest body, the side frame sections extending along a seat height direction and disposed at a separation from each other along a seat width direction; and an inclined wall portion that is provided between the side frame sections, that is inclined towards a seat front-rear direction front side with respect to the side frame sections such that a lower end portion of the inclined wall portion is positioned further to the seat front-rear direction front side than an upper end portion of the inclined wall portion, and that bears load acting on the headrest body from a seat front-rear direction rear side.
摘要:
In a seat device, a stay including grommets is set with bending rigidity towards the vehicle front lower than the bending rigidity towards the vehicle rear. Moreover, there is a large displacement of the headrest towards the vehicle front since the stay including the grommets has a lower bending rigidity towards the vehicle front than the bending rigidity towards the vehicle rear. The headrest can be promptly displaced towards the side of the head of the occupant due to setting the bending rigidity of the stay including the grommets, thereby enabling the time until the headrest contacts the head of the occupant to be shortened with a simple configuration.
摘要:
Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein X1 is optionally substituted heteroaryl or the like; Y1 is —NRACO— (CH2)0-2— or the like (wherein RA is a hydrogen or the like); Z1 is optionally substituted arylene or the like; and A1 is a ring represented by general formula (II) or (III):
摘要翻译:含有作为活性成分的通式(I)化合物,其前体药物,它们的药学上可接受的盐或它们的溶剂合物并且表现出血小板生成素受体激动剂的药物组合物:其中X 1是任选取代的 杂芳基等; Y 1是-NR A - (CH 2)2 - 或其类似物(其中R A是氢等等); Z 1是任选取代的亚芳基等; 和A 1是由通式(II)或(III)表示的环:
摘要:
A compound which inhibits both of EGF receptor tyrosine kinase and HER2 tyrosine kinase is provided.A compound represented by the general formula (I): wherein RX is a group represented by the formula: wherein R1 is a hydrogen atom, optionally substituted alkyl, etc.; Z is —O—, —N(R10)—, etc.; R10 is a hydrogen atom, alkyl, etc.; R2 is a hydrogen atom, optionally substituted alkyl, etc.; R18 is a hydrogen atom, optionally substituted alkyl, etc.; R19 is optionally substituted alkyl, etc.; W1 is an optionally substituted non-aromatic nitrogen-containing group; R17 is a hydrogen atom, optionally substituted alkyl, etc.; R3 and R4 are independently a hydrogen atom, optionally substituted alkyl, etc.; X is —O—, —S—, or —N(R12)—, etc.; R12 is a hydrogen atom, alkyl, etc.; and A is phenyl optionally having a substituent, etc., its pharmaceutically acceptable salt, or a solvate thereof.
摘要:
An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided.Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: wherein, R1 is a halogen atom or C1-C3 alkyloxy; R2 is C1-C8 alkyl; R3 is C1-C8 alkyl; R4 and R5 are each independently a fluorine atom or chlorine atom; R6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.
摘要:
A process for preparing an optically active 1,4-bridged-cyclohexane carboxylic acid derivatives which are clinically important thromboxane A.sub.2 thromboxane of formula (IV): ##STR1## wherein, R is phenyl or phenyl substituted with hydroxy, lower alkoxy, halogen, or lower alkyl; Y is oxygen, methylene, substituted methylene; m is 0 or 1; n is 0, 1 or 2; q is 3 or 4 with the proviso that when m is 1, n is 0 or 1 from an optically active norbornyl amine derivative.